Supplementary Methods and Materials from Breast Cancer Expressing the Activated HER2/neu Is Sensitive to Gefitinib &lt;i&gt;In vitro&lt;/i&gt; and &lt;i&gt;In vivo&lt;/i&gt; and Acquires Resistance through a Novel Point Mutation in the HER2/neu